TriAltus Bioscience

2:15 PM - 2:30 PM (PDT), Monday, June 13, 2022
TriAltus develops innovative tools for the production and purification of genetically engineered proteins. Our patented core technology is an engineered protein tag system that binds with 100,000x higher affinity than alternatives, resulting in 10-80x yield improvement and 99% purity in a single step.

We aim to democratize the process of protein production, levering superior yield to disrupt existing pricing conventions while maintaining high margins. Our products and services are being used by more than 100 customers worldwide, including two Nobel laureates; researchers at Harvard, Mayo Clinic and Scripps; as well as scientists at Merck, Moderna and Amgen.
Company Type:
Privately Funded Company
Company HQ State:
Alabama
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
Affinity membranes and RUO recombinant proteins
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
TriAltus Bioscience